Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 6/20 | 0.52 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 4/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24065100 | 1.00 | IGF1R (0.52) | IGF1RNEK1PAK4PAK1 | |
| SCHEMBL1164508 | 0.86 | IGF1R (0.65) | IGF1RNEK1PAK4PAK1 | |
| SCHEMBL14723540 | 0.84 | IGF1R (0.60) | IGF1RNEK1PAK4PAK1 | |
| SCHEMBL14723204 | 0.84 | IGF1R (0.60) | IGF1RNEK1PAK4PAK1 | |
| SCHEMBL14722650 | 0.80 | PAK4 (0.59) | IGF1RNEK1PAK4PAK1 | |
| SCHEMBL24065043 | 0.79 | PAK4 (0.79) | IGF1RNEK1PAK4PAK1 | |
| SCHEMBL14723359 | 0.79 | PAK1 (0.54) | IGF1RNEK1PAK4PAK1 | |
| SCHEMBL24065121 | 0.79 | IGF1R (0.51) | IGF1RNEK1PAK4PAK1 | |
| SCHEMBL24065156 | 0.77 | IGF1R (0.50) | IGF1RNEK1PAK4PAK1 | |
| SCHEMBL28664529 | 0.77 | IGF1R (0.50) | IGF1RNEK1PAK4PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2021-12-02 | — | — | US | disclosed |
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | IGF1R 1878/4885NEK1 890/4885PAK4 528/4885 |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | IGF1R 584/4885NEK1 94/4885PAK4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.